Taming the storm: potential anti-inflammatory compounds targeting SARS-CoV-2 MPro.

Area of Science:

• Drug Discovery
• Virology
• Immunology

Background:

• Severe COVID-19 involves a dangerous cytokine storm, worsening patient outcomes.
• Antiviral and anti-inflammatory compounds offer a dual therapeutic approach for COVID-19, effective at all disease stages.
• The SARS-CoV-2 main protease (MPro) is a key target for antiviral drug development due to its essential role in viral replication.

Purpose of the Study:

• To identify inhibitors of SARS-CoV-2 MPro that possess both antiviral and anti-inflammatory properties.
• To analyze the binding interactions of these compounds within the MPro active site.

Main Methods:

• Literature review to identify potential MPro inhibitors.
• Molecular docking simulations to analyze compound interactions with the SARS-CoV-2 MPro binding site.
• Classification of 18 selected compounds into five superclasses.

Main Results:

• Five compounds (GC-376, baicalein, naringenin, heparin, carmofur) demonstrated high potency against MPro (IC50 < 0.2 μM).
• These inhibitors target key inflammatory pathways (NF-κB, JAK/STAT, MAPK) implicated in COVID-19.
• Compounds bind to the MPro S1/S2 subsite, interacting with critical residues like the catalytic dyad and oxyanion hole.

Conclusions:

• Identified MPro inhibitors exhibit potential for alleviating lung edema and reducing cytokine release in COVID-19.
• These compounds represent promising candidates for further optimization as potential treatments for mild to severe COVID-19.